BioCryst ' s Rapivab (peramivir injection) Receives FDA Approval for a Pediatric Indication

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news